| Dr Stanley H Shrom, MD | |
|
4729 Us Highway 98 S, Lakeland, FL 33812-4323 | |
| (863) 646-5789 | |
| (863) 646-5834 |
| Full Name | Dr Stanley H Shrom |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 4729 Us Highway 98 S, Lakeland, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003851957 | NPI | - | NPPES |
| 29218 | Other | FL | BLUE CROSS BLUE SHIELD |
| 000891800 | Medicaid | FL | |
| P00723081 | Other | FL | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | ME103638 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stanley H Shrom, MD Po Box 10744, Clearwater, FL 33757 Ph: (727) 532-0002 | Dr Stanley H Shrom, MD 4729 Us Highway 98 S, Lakeland, FL 33812-4323 Ph: (863) 646-5789 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Arpida Ltd. has announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for intravenous iclaprim for the treatment of complicated skin and skin structure infections (cSSSI).
A team of researchers says it has discovered why so many people undergoing magnetic resonance imaging (MRI), especially in newer high-strength machines, get vertigo, or the dizzy sensation of free-falling, while inside or when coming out of the tunnel-like machine.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
The NHS has taken measures to stop patients from wrongfully claiming prescriptions for free. Prescription frauds, according to sources, cost the NHS £256 million annually. These measures would help reduce these costs by half.
› Verified 8 days ago
Dr. Matthew S. Smith, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 5015 Hancock Lake Rd, Lakeland, FL 33812 Phone: 863-581-7226 | |
James Allen Wilson, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 1600 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-680-7000 Fax: 866-264-8519 | |
Dr. Graham Foley Greene, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 3525 Lakeland Hills Blvd, Lakeland Regional Cancer Center, Lakeland, FL 33805 Phone: 863-603-6565 Fax: 863-904-1961 | |
Dr. Mark Joseph Swierzewski, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1600 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-680-7300 Fax: 866-264-8519 | |
David Lowell Bowers, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 3525 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-603-6565 Fax: 863-603-6564 | |
G Byron Hodge Jr., M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 1600 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-680-7000 Fax: 866-264-8519 |